News
-
Tirzepatide Diarrhea: How Long It Lasts
Diarrhea is common with tirzepatide, especially after treatment begins or the dose increases. It is usually temporary, but persistent symptoms can cause dehydration and deserve a clinician's attention.
-
Is Tirzepatide Safe? What the Evidence Shows
Safety is not a property of the molecule. It is the dose, the source of the vial, your own medical history, and whether a licensed clinician is accountable for the decision.
-
Oral Semaglutide: How the Semaglutide Pill Works
Estimated absolute bioavailability is about 0.4% to 1% for Rybelsus tablets and about 1% to 2% for Ozempic and Wegovy tablets; all three labels require fasting administration with up to 4 ounces of water and a 30-minute wait. Promise's compounded semaglutide formulation discussed here is an injectable solution.
-
Sermorelin vs Ipamorelin: Two Different Receptors
Sermorelin copies the hypothalamus and clears in about four minutes. Ipamorelin copies ghrelin and lasts roughly two hours. The receptor each one binds explains almost everything else about them.
-
Tesamorelin Ipamorelin: Two Receptors, One Vial
Two peptides, two pituitary receptors, one vial. Each half has a research record of its own; the combination has never been tested as a combination.
-
Tirzepatide vs Retatrutide: How They Compare
Tirzepatide is a dual GIP/GLP-1 agonist with completed phase 3 trials and approved U.S. indications. Retatrutide is an investigational triple agonist that cannot be prescribed here yet — and that, not potency, is the difference that matters.
-
Does Sermorelin Work? What Human Studies Show
Small human studies show that sermorelin can increase growth hormone output, but IGF-1 and body-composition results are inconsistent. Whether it is working should be judged with labs and a prescriber, not a feeling or a promised calendar.
-
Is Semaglutide Safe? What the Evidence Shows
Semaglutide has years of trial data and a defined risk profile, but safe is not universal. Eligibility depends on personal history, other medicines, monitoring and exactly what product is dispensed.
-
Tirzepatide and Thyroid Cancer: What We Know
The boxed warning comes from thyroid C-cell tumors in rats, not proof of human cancer. Human studies conflict, so MTC and MEN 2 history remains the decisive screening issue.
-
Tirzepatide Weight Loss Results by Month
In SURMOUNT-1, average weight loss reached 15.0% to 20.9% at 72 weeks, depending on dose. The first month was only the initiation phase, and results varied widely.
-
Does Semaglutide Cause Hair Loss?
In the pooled 68-week trials, hair loss was reported by 3% of adults on semaglutide 2.4 mg against 1% on placebo. Telogen effluvium after fast weight loss explains it better than any proven effect on the follicle.
-
MOTS-c Side Effects: What Is Known and What Is Not
No completed human trial has measured them. What gets sold as a MOTS-c side-effect profile is assembled from injection-site experience with subcutaneous peptides, from pharmacology, and from what a prescriber screens for.
-
Switching From Semaglutide to Tirzepatide
There is no validated milligram equivalence between the two molecules. Tirzepatide restarts at its own labeled starting dose no matter where the semaglutide dose ended, and a prescriber sets the timing.
-
Tirzepatide and Alcohol: The Risks That Matter
There is no alcohol contraindication in the labelling. The real issues are additive nausea, low blood sugar with certain diabetes medicines, a stomach that empties slowly, and pancreatitis risk arriving from two directions.
-
Tirzepatide for Sleep Apnea: What Was Approved
In December 2024 Zepbound became the first medicine approved in the United States for moderate-to-severe obstructive sleep apnea in adults with obesity. The trials behind it are specific, and so is what that approval does and does not cover.
-
PT-141 Nasal Spray: Why It Became an Injection
Bremelanotide really was developed as a nasal spray. That program was halted in 2007 over dose-related blood-pressure increases, and every version since has been a subcutaneous injection.
-
Semaglutide Cost: Brand, Self-Pay and Compounded
Wegovy lists near $1,350 a month and Ozempic near $1,040, while the manufacturer's own self-pay channel charges $349 and eligible Medicare beneficiaries now pay a $50 copay. Same molecule, four very different bills.
-
Semaglutide for Type 2 Diabetes: What Trials Show
Brand semaglutide is approved for glycemic control in adults with type 2 diabetes, and the trial record now runs past blood sugar into heart and kidney outcomes. Compounded semaglutide is a different thing again — here is what separates them.
-
Tesamorelin vs Sermorelin: What Actually Differs
Both are growth-hormone-releasing hormone analogues and they are not interchangeable: one is a 44-amino-acid molecule with a current US approval, the other a 29-amino-acid fragment whose branded product left the market in 2008.
-
How Long Does Semaglutide Stay in Your System?
Injectable semaglutide has an elimination half-life of about one week and can remain in circulation for roughly five to seven weeks after the last dose. Its effects fade on a curve, not at a single cutoff.
Page 14 of 18 · 344 articles